IP Library Granted Patent US 11,760,992
Granted Patent B2
US 11,760,992 · App. 17/820,242 · Granted Sep 19, 2023

Method for producing and purifying RNA, comprising at least one step of tangential flow filtration

Inventors: Andreas Funkner (Tübingen, DE); Stefanie Dorner (Tübingen, DE); Stefanie Sewing (Tübingen, DE); Johannes Kamm (Tübingen, DE); Norbert Broghammer (Tübingen, DE); Thomas Ketterer (Gomaringen, DE); Thorsten Mutzke (Reutlingen, DE)
Assignee: CureVac Manufacturing GmbH
C12N15/1017B01D61/145B01D71/12C12P19/34G01N30/02G01N2030/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,760,992
App. No.
17/820,242
Granted
Sep 19, 2023
Kind
B2
Abstract

The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).

Claims (51)

1. A method for producing purified RNA, comprising the steps of:

A1) providing a plasmid DNA encoding a RNA, wherein said RNA is 500 to 10000 nucleotides in length;

A2) linearizing the plasmid DNA to produce linearized DNA;

A3) ultrafiltering the linearized DNA by tangential flow filtration (TFF), to produce purified linearized DNA;

B1) transcribing the purified linearized DNA to produce transcribed RNA;

B2) treating the transcribed RNA with a DNase; and

C1) ultrafiltering the transcribed RNA by performing at least one step of TFF using a TFF membrane cassette having a molecular weight cutoff (MWCO) of less than or equal to 500 kDa, to produce the purified RNA.

2. The method of claim 1 , wherein the TFF membrane cassette has a MWCO of about 100 kDa to 300 kDa.

3. The method of claim 1 , wherein the TFF membrane cassette has a MWCO of about 300 kDa.

4. The method of claim 1 , wherein the TFF membrane cassette has a membrane comprising cellulose or a cellulose derivative.

5. The method of claim 1 , wherein the method comprises at least one step of DNA or RNA purification using anion exchange chromatography.

6. A method for producing purified RNA, comprising the steps of:

A1) providing a plasmid DNA encoding a RNA, wherein said RNA is 500 to 10000 nucleotides in length;

A2) linearizing the plasmid DNA to produce linearized DNA;

A3) ultrafiltering the linearized DNA by tangential flow filtration (TFF) to produce a purified linearized DNA;

B1) transcribing the purified linearized DNA in the presence of a cap analog to produce a transcribed capped RNA;

B2) treating the transcribed capped RNA with a DNase;

C1) ultrafiltering the transcribed capped RNA by at least one step of TFF with an aqueous salt solution using a TFF membrane cassette having a molecular weight cutoff (MWCO) of less than or equal to 500 kDa; and

C2) performing at least one further filtration using TFF, to obtain the purified RNA.

7. The method of claim 6 , wherein providing the plasmid DNA comprises purifying the plasmid DNA.

8. The method of claim 6 , wherein the TFF membrane cassette of step C1) has a MWCO of about 100 kDa to 300 kDa.

9. The method of claim 6 , wherein the TFF membrane cassette of step C1) has a MWCO of about 300 kDa.

10. The method of claim 6 , wherein the TFF membrane cassette comprises cellulose or a cellulose derivative.

11. The method of claim 7 , wherein the method comprises at least one step of DNA or RNA purification using anion exchange chromatography.

12. The method of claim 6 , wherein transcribing the purified linearized DNA is performed in the presence of a modified nucleotide to produce transcribed capped RNA having the modified nucleotide and wherein the modified nucleotide is 1-methyl-pseudouridine.

13. The method of claim 7 , wherein the method further comprises formulating the purified RNA.

14. The method of claim 13 , further comprising a filling step.

15. The method of claim 6 , wherein transcribing the purified linearized DNA is performed in the presence of spermidine.

16. The method of claim 15 , wherein transcribing the purified linearized DNA is performed in the presence of 0.1 mM to 10 mM spermidine.

17. The method of claim 16 , wherein step C1) produces RNA with a reduced level of spermidine relative to the level of spermidine in the transcribing step.

18. The method of claim 17 , comprising treating the transcribed capped RNA with DNaseI in the presence of CaCl 2 , following by addition of EDTA.

19. The method of claim 6 , wherein the TFF of step C2) is with a TFF membrane cassette.

20. The method of claim 19 , wherein the membrane cassette of step C2) has a MWCO of about 100 kDa to 300 kDa.

21. The method of claim 19 , wherein the membrane cassette of step C2) has a MWCO of about 300 kDa.

22. The method of claim 7 , wherein the method comprises at least one step of DNA or RNA purification using anion exchange chromatography.

23. The method of claim 6 , wherein the method comprises at least one further step of RNA purification or RNA concentration using TFF.

24. The method of claim 6 , wherein the method does not include a step for organic solvent extraction or alcohol precipitation of the transcribed capped RNA.

25. The method of claim 6 , wherein the method does not include a step for organic solvent extraction or alcohol precipitation of the plasmid DNA or the linearized DNA.

26. The method of claim 25 , wherein the transcribed capped RNA comprises a Cap1 5′ cap and a Poly(A) sequence of 50 to 250 nucleotides.

27. The method of claim 26 , wherein the transcribed capped RNA comprises a modified nucleotide, which is 1-methyl-pseudouridine.

28. The method of claim 27 , wherein linearizing the plasmid DNA is with a type II restriction endonuclease.

29. A method for producing a formulated purified mRNA, comprising the steps of:

A1) providing a plasmid DNA encoding a mRNA, wherein said mRNA is 500 to 5000 nucleotides in length and comprises a Poly(A) sequence of 50 to 250 nucleotides;

A2) linearizing the plasmid DNA to produce linearized DNA;

A3) ultrafiltering the linearized DNA by tangential flow filtration (TFF) to produce a purified linearized DNA;

B1) transcribing the purified linearized DNA in the presence of a cap analog, nucleoside triphosphates (NTPs), T7 polymerase, spermidine, salts and a buffer to produce a transcribed capped mRNA;

B2) treating the transcribed capped mRNA with a DNase followed by addition of EDTA;

C1) ultrafiltering the transcribed capped mRNA by at least one step of TFF with an aqueous salt solution using a TFF membrane cassette having a molecular weight cutoff (MWCO) of less than or equal to 500 kDa, thereby reducing the level of spermidine associated with the transcribed capped mRNA;

C2) performing at least one further filtration using TFF, to obtain the purified mRNA; and

D) formulating the purified mRNA by complexing the purified mRNA with a cationic compound, to obtain a formulated purified mRNA.

30. The method of claim 29 , wherein the TFF membrane cassette has a MWCO of about 300 kDa and comprises a stabilized cellulose-based TFF membrane.

Assignments (1)
CHANGE OF NAME Recorded Nov 12, 2022
From: CUREVAC REAL ESTATE GMBH
To: CUREVAC MANUFACTURING GMBH
Reel/Frame 061932/0502 →
Priority Claims (1)
WO PCT/EP2015/062002 · May 29, 2015 · international
Continuity (4)
Continuation 17591978 · Feb 3, 2022
Continuation 16934279 · Jul 21, 2020
Continuation 15580092
Related Publication 20230151352A1 · May 18, 2023
Cited By (3)
US 12,221,605 US 12,240,873 US 12,528,855